Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback